Tevogen Bio faces hurdles with unclear COVID-19 therapy demand, ambitious projections, and risks ahead. Click here to read an ...

Tesla’s financials are unraveling, with flat revenue, shrinking profits, and weakest performance among MAG7 in Q4 and FY 2024 ...

Apple Inc.'s market value declines amid tariff controversy. Discover why its valuation remains unattractive and growth ...

Recuresion Pharma (RXRX) stock and other AI-driven biotechs surge as FDA embraces computational models over animal testing ...

The 200DMA Signal suggests S&P 500 Index losses amidst U.S.-China tensions. Click for my look at technical triggers for the ...

Recursion Pharmaceuticals' stock is soaring today on news the FDA is planning on phasing out some animal testing, replacing ...

NVR faces short-term challenges but thrives on a 3.5M U.S. housing shortage. With a 25% upside, discover why it's a long-term ...

Celestica reports 21% YoY revenue growth in CY 2024, driven by CCS expansion. Click here to find out why CLS stock is a Buy.

Soaring rates, a falling dollar, and tariff-driven foreign outflows impact U.S. markets, bond yields, and stock valuations.

By James KnightleyThe Consumer Confidence Index published by the University of Michigan dropped 6.2 points to 50.8 in early ...

RTX Corporation is a strategic player in aerospace and defense, benefiting from economies of scale, cross-innovation, and ...

CoreWeave, Inc. IPO offers a compelling near-term trade despite structural flaws. Read more on CRWV stock prospects and why ...